Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO - Wikidata - wikimedia - TriplyDB

Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO

Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO

http://www.wikidata.org/entity/Q27684072

about

Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention Effect of redox modulating NRF2 activators on chronic kidney disease Emerging roles of Nrf2 signal in non-small cell lung cancer A generalizable platform for interrogating target- and signal-specific consequences of electrophilic modifications in redox-dependent cell signaling In Situ Observation of Thiol Michael Addition to a Reversible Covalent Drug in a Crystalline Sponge.The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.Chemical constituents from a Gynostemma laxum and their antioxidant and neuroprotective activities.Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity.Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasome Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators.Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway Pterisolic Acid B is a Nrf2 Activator by Targeting C171 within Keap1-BTB Domain.Andrographolide Activates Keap1/Nrf2/ARE/HO-1 Pathway in HT22 Cells and Suppresses Microglial Activation by Aβ42 through Nrf2-Related Inflammatory Response.Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.Structural basis of Keap1 interactions with Nrf2.Glycosylation of KEAP1 links nutrient sensing to redox stress signaling.Bardoxolone-methyl inhibits migration and metabolism in MCF7 cells.Absolute Amounts and Status of the Nrf2-Keap1-Cul3 Complex within Cells.CDDO and Its Role in Chronic Diseases.Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response.The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases.Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants.Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling.Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs.KEAP1 and Done? Targeting the NRF2 Pathway with Sulforaphane.C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape.Effects of 3-Bromo-4,5-dihydroisoxazole Derivatives on Nrf2 Activation and Heme Oxygenase-1 Expression

P2860

Q26778356-016681FA-B531-499C-B3F0-F9A9B2AEB9BC Q26827726-857B2D36-8311-4F79-87EE-769A1E3F6C08 Q28078928-89AFCA5B-658E-4690-B3C6-BB609B513EE7 Q28385286-6769475A-5E4B-4D31-A706-46BB7F60D588 Q31057399-6145FAAD-81F8-4FEA-BB5E-A2FF1CB122DB Q33659621-E5FAA4CD-5503-47D5-9663-374E4112B982 Q33721819-8133D4FD-C45F-4D73-874A-52C35FA486B6 Q35118710-B95516FD-D962-4E80-AAE2-CD3DD17E6844 Q35512908-0B1CE7F7-C69B-4362-8A9C-6E2A5A754934 Q35690117-58C9330C-F52E-46E9-8D8D-C52033BE394D Q35694891-55B517C6-C700-484D-AA64-784B618E8DD4 Q35753567-53C5F668-AF61-4DFE-9826-495B00641DDB Q36144939-521CB27A-0766-48AC-B22E-A78A20CD673B Q36277241-00E32CE2-455E-447F-86E3-17C14DB345A3 Q36497820-1DDF39FC-D8E6-4B16-89F7-E9F6BEBDED59 Q37714716-25B3254D-25F1-4E45-8719-E336044D8E31 Q38289589-B20E094A-0474-4E29-B96C-2DFE84F70312 Q38522152-22EBA530-2A00-4931-871D-7BC38A0B9EB6 Q38664878-29656396-6352-4C27-A9CF-0A987F508EE4 Q38712952-99DCCB00-F2EF-4B85-B659-451A0F5D7250 Q38742679-F2061839-9B21-43EA-82E0-F44B5802FD4C Q38807055-9185538A-5C3A-45D9-A458-EDEED58D4932 Q38822665-9C70F7B3-D4C6-43B6-91E4-053C5AA6BF70 Q38837451-E476987C-6F37-456E-B999-C2A8AEC97C8F Q38889475-DD4791ED-C5FB-4F0B-A874-03C83A315699 Q38920601-34753B44-C508-43F7-8F25-4C3BB60BE441 Q39270529-F3BB219D-700E-4BBE-9315-6C5704209684 Q39375357-C2ABDF59-CAAE-48DC-84AC-7353CCF359FA Q41634246-D7C65013-C721-4F55-AC7A-1A622CAF1CEC Q41914517-67F4D8EE-BF36-4009-976A-30310EC16F51 Q47903962-19D12743-4D6D-479E-A193-FDA88521897C Q48774191-AEB3B229-BD80-4AC4-8997-85088C5750ED Q49834826-1D0999D8-DFED-4899-A7CC-EC48C45D29DB Q55256229-A6964BEE-BF80-4782-8382-C371061A7EF7 Q58569406-AD3DC4F4-4B4A-43F5-8B78-7F7C53A65F59

P2860

Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO

http://www.wikidata.org/entity/Q27684072

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@ast

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@en

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@nl

type

label

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@ast

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@en

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@nl

prefLabel

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@ast

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@en

Structure of the BTB domain of ...... e triterpenoid antagonist CDDO

@nl

P1433

Q27684072-755B426D-9554-4472-BBB6-4AC965673337

P1476

Q27684072-B7ADE52C-CDAD-41AB-AFE2-8E91C8BD1E49

P2093

Q27684072-12D84018-EB94-47E8-9DA7-B9637CDFB254

Q27684072-310D3A85-1142-4F9A-8F34-4C6713B6B1B5

Q27684072-3CA63D0B-969E-4AED-AE62-89D4EA0F3AAA

Q27684072-4E38027F-0D1B-44E3-B0B7-2CD4243D35C7

Q27684072-500847E0-D3C3-417D-ABE3-5517DD68351C

Q27684072-561449DB-E58E-4ED1-9FEC-1BF271A77CF1

Q27684072-62C48A02-DEEF-4B8A-A6C7-22166B96DBBC

Q27684072-7584D0C7-445A-4E88-824C-7B3DC606D3A5

Q27684072-90BAB0CC-8928-4B7D-B0CC-58D54632D8BA

Q27684072-97365CCF-C51B-4BD0-88F0-DBE84BDAF28C

P2860

Q27684072-0441FC08-CC92-43F5-8968-4D587654179F

Q27684072-079336BC-8D79-40B1-8381-2717E6B59D75

Q27684072-0905F8A3-0999-4468-A560-56B8B2B6C3F3

Q27684072-0AC9ECD0-C96C-45AE-83D1-49CEF82BC61B

Q27684072-0B459815-081B-4790-A455-4ABE5BCACF61

Q27684072-0C8F3340-7CDE-4199-84CC-0E2CCD4801A8

Q27684072-0DD1C4F7-9B53-40E0-815C-F1A1F1560BB9

Q27684072-0E837B9D-E63A-4C43-9150-62D243E7D31E

Q27684072-166243A4-2371-489F-8817-4BB408BA0AC4

Q27684072-1806EEBD-5106-4365-9C6F-8046D6D0A85E

P304

Q27684072-ED4A470D-FBFA-4080-B317-0BD0682113E9

P31

Q27684072-01AF07C1-DD9D-41BD-AFD8-C301A580186D

P356

Q27684072-FFABC199-C580-499B-89A3-695CCA1DF015

P407

Q27684072-E51286AC-B95A-4F38-AA1A-EF04141106F0

P433

Q27684072-16AF1AC2-2677-4AD5-94F3-5943AFD2BB3F

P478

Q27684072-E187515A-5C97-4B6B-8BF7-18B2CE51F69C

P50

Q27684072-82B6906A-39D4-4FFD-A51F-DE96DC04C617

P577

Q27684072-B1612A90-AE1B-4EDC-AC35-ABDE3A5280D2

P5875

Q27684072-68DF2D9C-EF83-4094-86A7-EF82A7057DC0

P698

Q27684072-2C242371-D427-47EB-B41E-47D40AC45000

P932

Q27684072-F0883A3F-0EE6-4039-A75A-351DE379B79A

P356

JOURNAL.PONE.0098896

P1433

P1476

Structure of the BTB Domain of ...... e Triterpenoid Antagonist CDDO

@en

P2093

Anne Cleasby

http://www.w3.org/2001/XMLSchema#string

Caroline Richardson

http://www.w3.org/2001/XMLSchema#string

Hongwei Qi

http://www.w3.org/2001/XMLSchema#string

James F Callahan

http://www.w3.org/2001/XMLSchema#string

Jeff Yon

http://www.w3.org/2001/XMLSchema#string

Jeffrey K Kerns

http://www.w3.org/2001/XMLSchema#string

Nestor Concha

http://www.w3.org/2001/XMLSchema#string

Pamela A Williams

http://www.w3.org/2001/XMLSchema#string

Paris Ward

http://www.w3.org/2001/XMLSchema#string

Philip J Day

http://www.w3.org/2001/XMLSchema#string

P2860

Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligase

The Protein Data Bank

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.

Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity

Sequence and structural analysis of BTB domain proteins

Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response

Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases

Insights into strand exchange in BTB domain dimers from the crystal structures of FAZF and Miz1

Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function

P304

e98896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0098896

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262846504

http://www.w3.org/2001/XMLSchema#string

P698

24896564

http://www.w3.org/2001/XMLSchema#string

P932

4045772

http://www.w3.org/2001/XMLSchema#string